Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

Open access
Ginès, Pere, Castera, Laurent, Lammert, Frank, Graupera, Isabel, Serra‐Burriel, Miquel, Allen, Alina M., Wong, Vincent Wai‐Sun, Hartmann, Phillipp, Thiele, Maja, Caballeria, Llorenç, de Knegt, Robert J., Grgurevic, Ivica, Augustin, Salvador, Tsochatzis, Emmanuel A., Schattenberg, Jörn M., Guha, Indra Neil, Martini, Andrea, Morillas, Rosa M., Garcia‐Retortillo, Montserrat, de Koning, Harry J., Fabrellas, Núria, Pich, Judit, Ma, Ann T., Diaz, M. Alba, Roulot, Dominique, Newsome, Philip N., Manns, Michael, Kamath, Patrick S., Krag, Aleksander, for the LiverScreen Consortium Investigators·2022·Hepatology

Abstract

Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non‐alcoholic fatty liver disease and alcohol‐related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at‐risk populations. Thus far, a limited number of population‐based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate −18% to 27%‐in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.32163

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 291

Metadata

Authors
Ginès, P., Castera, L., Lammert, F., Graupera, I., Serra‐Burriel, M., Allen, A. M., Wong, V. W., Hartmann, P., Thiele, M., Caballeria, L., de Knegt, R. J., Grgurevic, I., Augustin, S., Tsochatzis, E. A., Schattenberg, J. M., Guha, I. N., Martini, A., Morillas, R. M., Garcia‐Retortillo, M., de Koning, H. J., Fabrellas, N., Pich, J., Ma, A. T., Diaz, M. A., Roulot, D., Newsome, P. N., Manns, M., Kamath, P. S., Krag, A., & for the LiverScreen Consortium Investigators
Venue
Hepatology
Published
2021-12-10
Volume
75
Issue
1
Pages
219-228
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W3199767770
Cited by
291
References
40
FWCI
25.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. https://app.cochat.ai/papers/10.1002/hep.32163
The paper
Ginès, P., Castera, L., Lammert, F., Graupera, I., Serra‐Burriel, M., Allen, A. M., Wong, V. W., Hartmann, P., Thiele, M., Caballeria, L., de Knegt, R. J., Grgurevic, I., Augustin, S., Tsochatzis, E. A., Schattenberg, J. M., Guha, I. N., Martini, A., Morillas, R. M., Garcia‐Retortillo, M., . . . for the LiverScreen Consortium Investigators. (2022). Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. https://doi.org/10.1002/hep.32163

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.